IL23A

(redirected from IL-23)

IL23A

A gene on chromosome 12q13.13 that encodes interleukin-23A, a cytokine which associates with IL-12B to form IL-23, a heterodimeric cytokine involved in innate and adaptive immunity. IL-23 binds to a heterodimeric receptor complex composed of IL12RB1 and IL23R, activates the JAK-START signalling cascade, stimulates memory T cells and promotes production of proinflammatory cytokines.
 
Molecular pathology
IL-23 may induce autoimmune inflammation and play a role in tumourigenesis.
Mentioned in ?
References in periodicals archive ?
Risankizumab is an investigational compound that is designed to selectively block IL-23 by binding to its p19 subunit.
These data are especially important in further understanding the role IL-23 plays in the onset and progression of plaque psoriasis, unique insights that we continue to apply in our innovation efforts with TREMFYA and the IL-23 pathway.
These long-term, open-label extensions of previously reported phase 3, randomized, double-blind clinical trials provided evidence of multiple advantages for IL-23 inhibition.
The investigational compound, which has been designed to selectively inhibit IL-23 by binding to its p19 subunit, was assessed in the late-stage study named IMMhance.
In a previous study, we found increased IL-17 and IL-23 expression in women with RSA (16).
Synovial fibroblasts directly induce Th17 pathogenicity via the cyclooxygenase/prostaglandin E2 pathway, independent of IL-23.
In particular, myeloid cell secretion of IL-1, IL-23, and IL-12 activates IL-17-producing T cells ([T.
IL-12, IL-17 and IL-23 are the targets of future anticytokine therapies.
One report showed that in IL-23 subunit p19-deficient mice, there was an almost total loss of Th17, but intriguingly the absence of Th17 had little effect in controlling the infection.
The expressions of IL-10, TGF-b1, IL-17 and IL-23 mRNA and protein were detected using real-time fluorescence quantitative PCR and ELISA.
Targeting IL-23 alone may allow for a broader therapeutic window versus IL12/23 targeting therapies and may translate into better efficacy.
IL-23 and TGF-[beta]1 levels as potential predictive biomarkers in treatment of bipolar I disorder with acute manic episode.